GSK shelves camlipixant after mixed Ph3 chronic cough results, boosting TRVI premarket
GSK shelves camlipixant after mixed Ph3 chronic cough results, boosting TRVI premarket
- GSK reported CALM-1 met primary cough frequency reduction endpoint at week 12 (50mg BID) but CALM-2 missed at week 24; 25mg failed both; secondaries unmet.
- GSK decided not to advance camlipixant (P2X3 antagonist from $2B Bellus deal) further in refractory chronic cough (RCC), citing insufficient efficacy to transform care.
- TRVI's Haduvio (oral nalbuphine ER, distinct kappa-opioid agonist MOA) positioned as beneficiary, especially in IPF-related chronic cough where it has Phase 3 plans.
- Retail chatter and biotech investors piled into TRVI on the news, viewing GSK setback as expanding opportunity in high-unmet-need cough markets.
- ERS Cough Conference (July 15-17, London) ongoing with Trevi CEO/CDO attending; no new Trevi data announced today.
- TRVI shares gained ~8-11% in premarket July 17 after closing at $17.36 prior day, extending recent run to all-time highs.
- Analysts maintain bullish targets ($20-29 range) on TRVI's cash runway into 2030 post-2026 offering and advancing pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.